

Publisher: Bentham Science Publishers
E-ISSN: 1873-5592|6|4|419-425
ISSN: 1389-4501
Source: Current Drug Targets, Vol.6, Iss.4, 2005-06, pp. : 419-425
Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.
Abstract
Related content








By Smetana Karel André Sabine Kaltner Herbert Kopitz Jürgen Gabius Hans-Joachim
Expert Opinion on Therapeutic Targets, Vol. 17, Iss. 4, 2013-04 ,pp. :


Galectin-1 as a Potential Therapeutic Agent for Amyotrophic Lateral Sclerosis
Current Drug Targets, Vol. 6, Iss. 4, 2005-06 ,pp. :